Created at	Source	Raw Value	Validated value
Feb. 4, 2023, 8 p.m.	usa	Geometric Mean Titer(GMT) of neutralizing antibody to the SARS-CoV-2 measured by wild-type virus neutralization assays;Geometric Mean Titer(GMT) of neutralizing antibody to the SARS-CoV-2 measured by wild-type virus neutralization assays;Percentage of participants with ≥ 4-fold rise in wild-type virus neutralizing antibody titer from baseline	Geometric Mean Titer(GMT) of neutralizing antibody to the SARS-CoV-2 measured by wild-type virus neutralization assays;Geometric Mean Titer(GMT) of neutralizing antibody to the SARS-CoV-2 measured by wild-type virus neutralization assays;Percentage of participants with ≥ 4-fold rise in wild-type virus neutralizing antibody titer from baseline
Aug. 27, 2021, 8 p.m.	usa	Geometric Mean Titer(GMT) of neutralizing antibody to the SARS-CoV-2 measured by wild-type virus neutralization assays;Percentage of participants with ≥ 4-fold rise in wild-type virus neutralizing antibody titer from baseline	Geometric Mean Titer(GMT) of neutralizing antibody to the SARS-CoV-2 measured by wild-type virus neutralization assays;Percentage of participants with ≥ 4-fold rise in wild-type virus neutralizing antibody titer from baseline
Aug. 17, 2021, 6 p.m.	usa	Geometric Mean Titer(GMT) of neutralizing antibody to the SARS-CoV-2;Percentage of participants with ≥ 4-fold rise in wild-type virus neutralizing antibody titer from baseline	Geometric Mean Titer(GMT) of neutralizing antibody to the SARS-CoV-2;Percentage of participants with ≥ 4-fold rise in wild-type virus neutralizing antibody titer from baseline